ECKERT ROBERT 4

4 · AMGEN INC · Filed May 21, 2026

AI-generated summary of this filing

Updated May 21, 2026

Amgen (AMGN) Director Robert Eckert Receives RSU Award

What Happened

Robert Eckert, a director of Amgen Inc., was granted 665 restricted stock units (RSUs) on May 19, 2026. The grant is reported at $0.00 per share (no cash paid) — typical for RSU awards — so reported cash consideration = $0. Vested RSUs are paid in shares of Amgen common stock on a one-for-one basis.

Key Details

Transaction date: 2026-05-19; filing date (Form 4): 2026-05-21 (appears filed within the normal Section 16 reporting window).
Grant: 665 RSUs @ $0.00 (reported acquisition via award).
Shares owned after transaction: not specified in the provided excerpt.
Footnotes:
- F1: RSUs were granted under Amgen’s 2009 Director Incentive Program (Second Amended and Restated 2009 Equity Incentive Plan) and vested immediately; vested RSUs are paid one-for-one in shares and may be deferred by the director per an elected schedule.
- F2: Filing notes dividend equivalents (DEs) are credited to unvested RSUs and are paid out in shares per the vesting schedule (the footnote references DEs and their treatment, including cash for fractional shares).

Context

This transaction is an award/grant (not an open‑market buy or sale). Awards to directors are routine compensation and do not in themselves indicate a buy or sell signal by the insider.
Because the RSUs vested immediately, Eckert will receive shares (unless he elected deferral) rather than exercising options or paying cash.

Form 4

Period: 2026-05-19

Director

Transactions

Footnotes (2)

[F1]The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case payment will occur according to the elected deferral schedule.
[F2]These shares include 3,943 DEs granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Signature

/s/ Robert A. Eckert|2026-05-19

1 file